These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 1701660)

  • 1. The clinical development of a 5 alpha-reductase inhibitor, finasteride.
    Stoner E
    J Steroid Biochem Mol Biol; 1990 Nov; 37(3):375-8. PubMed ID: 1701660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Finasteride for benign prostatic hyperplasia.
    Hasinski S; Miller JL; Rose LI
    Am Fam Physician; 1992 Nov; 46(5):1511-4. PubMed ID: 1279965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Finasteride: a 5 alpha-reductase inhibitor.
    Steiner JF
    Clin Pharm; 1993 Jan; 12(1):15-23. PubMed ID: 7679063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen.
    Geller J
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1552-5. PubMed ID: 1699965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormonal effects of a 5 alpha-reductase inhibitor (finasteride) on hormonal levels in normal men and in patients with benign prostatic hyperplasia.
    Vermeulen A; Giagulli VA; De Schepper P; Buntinx A
    Eur Urol; 1991; 20 Suppl 1():82-6. PubMed ID: 1722168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Castration-like effects on the human prostate of a 5 alpha-reductase inhibitor, finasteride.
    Geller J; Sionit L
    J Cell Biochem Suppl; 1992; 16H():109-12. PubMed ID: 1283893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia.
    McConnell JD; Wilson JD; George FW; Geller J; Pappas F; Stoner E
    J Clin Endocrinol Metab; 1992 Mar; 74(3):505-8. PubMed ID: 1371291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G; Rittmaster RS; Klocker H
    World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia.
    Guess HA; Heyse JF; Gormley GJ
    Prostate; 1993; 22(1):31-7. PubMed ID: 7678930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C19 and C21 5 beta/5 alpha metabolite ratios in subjects treated with the 5 alpha-reductase inhibitor finasteride: comparison of male pseudohermaphrodites with inherited 5 alpha-reductase deficiency.
    Imperato-McGinley J; Shackleton C; Orlic S; Stoner E
    J Clin Endocrinol Metab; 1990 Mar; 70(3):777-82. PubMed ID: 1689740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical effects of a 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study Group.
    Stoner E
    J Urol; 1992 May; 147(5):1298-302. PubMed ID: 1373779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of finasteride on the volume of the peripheral and periurethral zones of the prostate in men with benign prostatic hyperplasia.
    Tempany CM; Partin AW; Zerhouni EA; Zinreich SJ; Walsh PC
    Prostate; 1993; 22(1):39-42. PubMed ID: 7678931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Finasteride: the first 5 alpha-reductase inhibitor.
    Sudduth SL; Koronkowski MJ
    Pharmacotherapy; 1993; 13(4):309-25; discussion 325-9. PubMed ID: 7689728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5 alpha-metabolism in finasteride-treated subjects and male pseudohermaphrodites with inherited 5 alpha-reductase deficiency. A review.
    Imperato-McGinley J
    Eur Urol; 1991; 20 Suppl 1():78-81. PubMed ID: 1722167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G; Rittmaster RS; Klocker H
    Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term urodynamic effects of finasteride in benign prostatic hyperplasia: a pilot study.
    Kirby RS; Vale J; Bryan J; Holmes K; Webb JA
    Eur Urol; 1993; 24(1):20-6. PubMed ID: 7689971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia].
    Bartsch G; Rittmaster RS; Klocker H
    Urologe A; 2002 Sep; 41(5):412-24. PubMed ID: 12426858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group.
    Gormley GJ; Stoner E; Bruskewitz RC; Imperato-McGinley J; Walsh PC; McConnell JD; Andriole GL; Geller J; Bracken BR; Tenover JS
    N Engl J Med; 1992 Oct; 327(17):1185-91. PubMed ID: 1383816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
    Habib FK; Ross M; Tate R; Chisholm GD
    Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity.
    Imperato-McGinley J; Gautier T; Cai LQ; Yee B; Epstein J; Pochi P
    J Clin Endocrinol Metab; 1993 Feb; 76(2):524-8. PubMed ID: 8381804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.